Advertisement

Urinary dopamine sulfate: regulations and significance in neurological disorders

  • E. Kienzl
  • K. Eichinger
  • E. Sofic
  • K. Jellinger
  • P. Riederer
  • W. Kuhn
  • G. Fuchs
  • G. Laux
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

Dopamine-3-O-sulfate (DA-3-O-S) and dopamine-4-O-sulfate (DA-4-O-S) are important end products of L-dopa metabolism. Therefore they may give indications of disturbances in the peripheral metabolism of catecholamines, when measured in urine samples of patients with Parkinson’s disease (PD). In addition, information about the reliability of DA sulfatation after L-dopa therapy may be of significance for its role in the elimination of DA from the peripheral nervous system.

Although DA-3-O-S appears to be the predominant sulfo-conjugate in urine, there are no changes in PD nor in depression syndrome compared to controls with or without other neurological disorders. By contrast, DA-4-O-S is significantly decreased in de novo PD subjects. However, a similar reduction is notable in patients with other neurological disorders. In depressed persons the loss of this compound was less pronounced as compared to de novo PD. Treatment with combined L-dopa therapy caused increased excretion of DA-3-O-S, while changes in DA-4-O-S were only marginal. It is concluded that urinary DA-3-O-S cannot be used as marker for PD, while DA-4-O-S is significantly reduced in a variety of neurological disorders and in particular in de novo PD. Further studies are necessary to elucidate its role as possible peripheral marker to distinguish preclinical PD and depression syndrome.

Keywords

Ergot Alkaloid Aryl Sulfatase Dopamine Metabolite High Performance Liquid Chromato Depression Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bacopoulos NG, Hattox SE, Roth RH (1979) 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 56:225–236.PubMedCrossRefGoogle Scholar
  2. Bailey EV, Stone TW (1975) The mechanism of action of amantadine in parkinsonism — a review. Arch Int Pharmacodyn 216:246–262.PubMedGoogle Scholar
  3. Barbeau A (1969) Parkinson’s disease as a systemic disorder. In: Gillingham FJ, Sonaldson ML (eds) 3rd Symp. on Parkinson’s disease. Livingstone, Edinburg, pp 66-73.Google Scholar
  4. Bronaugh RL, Mattox SE, Hoehn MM, Murphy RC, Rutledge CO (1975) The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of parkinsonian patients. J Pharmacol Exp Ther 195:441–452.PubMedGoogle Scholar
  5. Buu NT (1985) Dopamine sulfoconjugation in the rat brain: regulation by monoamine oxidase. J Neurochem 45(2): 470–476.PubMedCrossRefGoogle Scholar
  6. Elchisak MA (1987) Analytical techniques for the determination of phenolic amine neurotransmitter conjugates. Life Sci 41(7):913–916.PubMedCrossRefGoogle Scholar
  7. Hoehn MM and Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology (Minneap) 17:427–442.Google Scholar
  8. Jellinger K (1989) Pathology of Parkinson’s syndrome. In: Calne DB (ed) Handbook of experimental pharmacology, vol 88. Springer, Berlin Heidelberg New York Tokyo, pp 47–112.Google Scholar
  9. Jenner NW, Rose FA (1973) Studies on the separation of 3,4-dihydroxy-phenylethylamine (dopamine) and related compounds by rat tissues. Biochem J 135:109–114.PubMedGoogle Scholar
  10. Johnson CA, Baker CA, Smith RT (1980) Radioenzymatic assay of sulphate conjugates of catecholamines and DOPA in plasma. Life Sci 26:1591–1598.PubMedCrossRefGoogle Scholar
  11. Kienzl E, Eichinger K (1988) Preparation of dopamine 3-O-sulfate and dopamine 4-O-sulfate as reference substances and high performance liquid Chromatographie trace determination. J Chromatogr 430:263–269.PubMedCrossRefGoogle Scholar
  12. Kienzl E, Eichinger K, Jellinger K, Kuhn W, Fuchs G, Riederer R (1990) Dopamine-sulfate conjugates in Parkinson’s disease. In: New vistas in drug research. Springer, Wien New York (in press).Google Scholar
  13. Lenman JAR, Turnbull MJ, Reid A, Fleming AM (1977) Urinary monoamine metabolite excretion in disorders of movement. J Neurol Sci 32:219–225.PubMedCrossRefGoogle Scholar
  14. Quick H, Sourkes TL (1977) Central dopaminergic and serotoninergic systems in the regulation of adrenal tyrosine hydroxylase. J Neurochem 28:137–147.CrossRefGoogle Scholar
  15. Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic cncephalopathies. J Neural Transm [Suppl] 14:121–131.Google Scholar
  16. Rivett AJ, Eddy BJ, Roth JA (1982) Contribution of sulfate conjugation, deamination and O-methylation to metabolism of dopamine and norepinephrine in human brain. J Neurochem 39:1009–1016.PubMedCrossRefGoogle Scholar
  17. Rivett AJ, Francis A, Whittemore R, Roth JA (1984) Sulfate conjugation of dopamine in rat brain: regional distribution of activity and evidence for neuronal localisation. J Neurochem 5:1444–1448.CrossRefGoogle Scholar
  18. Rutledge CD, Hoehn M (1973) Sulfate conjugation and L-dopa treatment of parkinsonian patients. Nature 244:447–450.PubMedCrossRefGoogle Scholar
  19. Scott MC, Elchisak MA (1983) Cardiovascular effects of dopamine sulfate in anesthetized dogs. Fed Proc 42:1363.Google Scholar
  20. Sofie E (1986) Thesis, Techn Univ Vienna, Austria.Google Scholar
  21. Van Loon GR, Sole M J, Bain J (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28:425–434.PubMedCrossRefGoogle Scholar
  22. Van Loon GR (1980) Abnormal catecholamine mechanisms in hypothalamicpituitary disorders. Metabolism 29(11) [Suppl] 1:1198–1202.PubMedCrossRefGoogle Scholar
  23. Westerink BHC, ten Kate N (1986) 24 h excretion patterns of free, conjugated and methylated catecholamines in man. J Clin Chem Clin Biochem 24:513–519.PubMedGoogle Scholar
  24. Yamamoto T, Yamatodani A, Nishimura AM (1985) Determination of dopamine-3-and-4-O-sulfate in human plasma and urine by anion-exchange high-performance liquid chromatography with fluorimetric detection. J Chromatogr 342:261–267.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • E. Kienzl
    • 1
  • K. Eichinger
    • 2
  • E. Sofic
    • 3
  • K. Jellinger
    • 1
  • P. Riederer
    • 3
  • W. Kuhn
    • 3
  • G. Fuchs
    • 4
  • G. Laux
    • 3
  1. 1.Ludwig Boltzmann Institute of Clinical NeurobiologyLainz-HospitalWienAustria
  2. 2.Institute of Organic ChemistryTechnical UniversityViennaAustria
  3. 3.Clinical Neurochemistry Section, Department of PsychiatryUniversity of Würzburg School of MedicineWürzburgFederal Republic of Germany
  4. 4.Parkinson Clinic, WohlfahrtFederal Republic of Germany

Personalised recommendations